CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for IGC Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

IGC Pharma Inc
10224 Falls Road
Phone: (301) 529-4996p:301 529-4996 POTOMAC, MD  20854  United States Ticker: IGCIGC
Business Summary
IGC Pharma, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to develop treatments for Alzheimer's and metabolic disorders. The Company's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The Company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. It is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20253/31/2025YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Richard K.Prins 68 1/1/2012 5/22/2007
President, Chief Executive Officer, Director RamMukunda 66 1/1/2012 4/29/2005
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director ClaudiaGrimaldi 54 5/1/2022 1/1/2016
Independent Director Terry L.Lierman 77 3/12/2024 3/12/2024
Independent Director JamesMoran 80 1/18/2022 1/18/2022

Subsidiaries
Business Name Address City State/Province Country
Holi Hemp LLC 4336 Montgomery Ave Bethesda MD United States

Business Names
Business Name
Cabaran Ultima Sdn Bhd
Hamsa Biopharma India Pvt. Ltd.
HH Processors, LLC
17 additional Business Names available in full report.

General Information
Number of Employees: 70 (As of 3/31/2025)
Outstanding Shares: 95,818,023 (As of 1/5/2026)
Shareholders: 46
Stock Exchange: ASE
Federal Tax Id: 202760393
Fax Number: (240) 465-0273


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, February 1, 2026